Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.49 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 5/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434588 | 0.87 | HTR6 (0.52) | HTR6HTR2CHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL2079115 | 0.87 | HTR6 (0.52) | HTR6HTR2CHTR2AHTR7DRD2 | |
| SCHEMBL5321082 | 0.83 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR7DRD2 | |
| SCHEMBL17229878 | 0.81 | CCNT1 (0.59) | HTR6HTR2CHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL17222962 | 0.81 | CCNT1 (0.59) | HTR6HTR2CHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL29915735 | 0.81 | CCNT1 (0.59) | HTR6HTR2CHTR2AHTR7DRD2 | |
| SCHEMBL1513540 | 0.80 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL29882492 | 0.80 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR7DRD2 | |
| SCHEMBL24157910 | 0.78 | HTR2C (0.50) | HTR6HTR2CHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL17223043 | 0.78 | HTR2C (0.50) | HTR6HTR2CHTR2AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HTR6 2254/4885HTR2C 1146/4885HTR2A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.